AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Apr 18 2018 AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
- Feb 28 2018 AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
- Feb 12 2018 AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
- Feb 8 2018 AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)